Related Experiment Videos
Monoclonal antibody MT1: a marker for Langerhans cell histiocytosis
1Department of Pathology, Women's College Hospital, Toronto, Ontario, Canada.
Insights
The monoclonal antibody MT1 can help diagnose Langerhans cell histiocytosis (LCH) in paraffin sections. Combined with S-100 protein staining, MT1 offers a reliable diagnostic panel for LCH.
Area of Science:
- Immunohistochemistry
- Histopathology
- Oncology
Background:
- Langerhans cell histiocytosis (LCH) diagnosis relies on identifying specific cellular markers.
- S-100 protein is a common marker for LCH but lacks specificity.
- CD1 (Leu 6) is specific for LCH but requires frozen tissue, limiting its routine use.
Purpose of the Study:
- To evaluate the diagnostic utility of monoclonal antibodies MT1, MT2, MB2, and LN1 in paraffin-embedded LCH tissues.
- To identify a panel of antibodies for reliable LCH diagnosis on routinely processed tissue sections.
Main Methods:
- Immunohistochemical staining was performed on paraffin-embedded tissue sections from 20 LCH cases.
- Monoclonal antibodies MT1, MT2, MB2, and LN1 were tested.
- Staining patterns were compared with S-100 protein and other histiocytic lesions.
Main Results:
- Pathologic Langerhans cells in all 20 LCH cases showed positive staining exclusively with MT1.
- MT1 staining was consistently negative in other S-100 protein-positive lesions.
- MT1 also stained positive in some cutaneous histiocytic and mast cell lesions that were S-100 protein negative.
Conclusions:
- The monoclonal antibody MT1 is a valuable additional marker for diagnosing Langerhans cell histiocytosis.
- A diagnostic panel comprising MT1 and S-100 protein can be effectively used on routine paraffin-embedded sections for LCH.
- This antibody panel enhances diagnostic accuracy and accessibility for LCH.
Abstract:
Langerhans cells and their pathologic counterparts can be identified in paraffin sections using immunohistochemical staining for S-100 protein. This procedure is useful in confirming a diagnosis of Langerhans cell histiocytosis (LCH). However, many other cell types are also positive for S-100 protein. Positive staining for CD1 (Leu 6) supports a diagnosis of LCH, but requires frozen tissue. A panel of antibodies would be desirable in confirming a diagnosis of LCH, particularly if these antibodies could be used on paraffin-embedded material. We studied the pattern of staining for commercially available monoclonal antibodies MT1, MT2, MB2, and LN1, which were originally marketed as lymphocyte markers, using paraffin-embedded tissue sections of cases of LCH. In all 20 cases pathologic Langerhans cells stained positively with MT1 only. Various other S-100 protein-positive lesions were also examined with MT1 and were consistently negative for MT1. Other cutaneous histiocytic and mast cell lesions were positive with MT1, but S-100 protein negative. Our results demonstrate that the monoclonal antibody MT1 serves as an additional marker for LCH and, together with S-100 protein, would make up a diagnostic panel of antibodies for LCH to be used on routine paraffin-embedded sections.